Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (41-50 of 464) with videos related to

Pageof 47
Sort By:
Alimentary Pharmacology & Therapeutics|November 10, 2018
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximabBrian G Feagan, Gordon Lam, Christopher Ma, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|November 18, 2017
Biosimilars: State of Clinical and Regulatory ScienceAgnes Victoria Klein, Jian Wang, Brian G Feagan, et al.
Journal of Crohn'S & Colitis|April 3, 2012
The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapySimon Travis, Brian G Feagan, Paul Rutgeerts, et al.
The Cochrane Database of Systematic Reviews|May 10, 2016
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisYongjun Wang, Claire E Parker, Brian G Feagan, et al.
Expert Opinion on Drug Safety|March 10, 2017
The safety of vedolizumab for the treatment of ulcerative colitisGregor Novak, Pieter Hindryckx, Reena Khanna, et al.
Gastroenterology & Hepatology|August 29, 2017
Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel DiseaseReena Khanna, Barrett G Levesque, William J Sandborn, et al.
Journal of Clinical Gastroenterology|April 9, 2005
Unemployment and disability in patients with moderately to severely active Crohn's diseaseBrian G Feagan, Mohan Bala, Songkai Yan, et al.
Inflammatory Bowel Diseases|September 18, 2010
Introduction to Cochrane systematic reviewsBrian G Feagan, John W McDonald, Nilesh Chande, et al.
Drug Safety|March 5, 2019
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative ColitisRobert Battat, Christopher Ma, Vipul Jairath, et al.
Best Practice & Research. Clinical Gastroenterology|July 23, 2019
IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?Christopher Ma, Remo Panaccione, Reena Khanna, et al.
Pageof 47

Showing results (41-50 of 464) with videos related to

Sort By:
Pageof 47
Alimentary Pharmacology & Therapeutics|November 10, 2018
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximabBrian G Feagan, Gordon Lam, Christopher Ma, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|November 18, 2017
Biosimilars: State of Clinical and Regulatory ScienceAgnes Victoria Klein, Jian Wang, Brian G Feagan, et al.
Journal of Crohn'S & Colitis|April 3, 2012
The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapySimon Travis, Brian G Feagan, Paul Rutgeerts, et al.
The Cochrane Database of Systematic Reviews|May 10, 2016
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisYongjun Wang, Claire E Parker, Brian G Feagan, et al.
Expert Opinion on Drug Safety|March 10, 2017
The safety of vedolizumab for the treatment of ulcerative colitisGregor Novak, Pieter Hindryckx, Reena Khanna, et al.
Gastroenterology & Hepatology|August 29, 2017
Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel DiseaseReena Khanna, Barrett G Levesque, William J Sandborn, et al.
Journal of Clinical Gastroenterology|April 9, 2005
Unemployment and disability in patients with moderately to severely active Crohn's diseaseBrian G Feagan, Mohan Bala, Songkai Yan, et al.
Inflammatory Bowel Diseases|September 18, 2010
Introduction to Cochrane systematic reviewsBrian G Feagan, John W McDonald, Nilesh Chande, et al.
Drug Safety|March 5, 2019
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative ColitisRobert Battat, Christopher Ma, Vipul Jairath, et al.
Best Practice & Research. Clinical Gastroenterology|July 23, 2019
IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?Christopher Ma, Remo Panaccione, Reena Khanna, et al.
Pageof 47